Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 228

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 228
---
 reporting in accordance with the provisions of the Sarbanes -OxleyAct. APx cannot assure you that the measures it has taken to date, and actions it may take in the future, will be sufficient to remediate the control deficiencies that led to these material weaknesses in its internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. Additionally, when evaluating internal controls over financial reporting in the future, APx may identify additional material weaknesses that it may not be able to remediate in advance to the applicable reporting deadlines imposed upon us once it is required to comply with the management assessment reporting requirements of Section 404 of the Sarbanes -OxleyAct. If APx identifies any additional material weaknesses in its internal control over financial reporting or it is unable to remediate the material weakness described above or comply with the requirements of Section 404 of the Sarbanes -OxleyAct in a timely manner or its independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of its internal control over financial reporting once it are no longer an emerging growth company, or APx is unable to conclude in its quarterly and annual reports that its disclosure controls and procedures are effective, investors may lose confidence in the accuracy and completeness of its financial reports and the market price of APx’s ordinary shares could be negatively affected, and it could become subject to investigations by the stock exchange on which its securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. If APx fails to remediate any material weakness, its financial statements could be inaccurate, and it could face restricted access to capital markets. 95 There are no assurances that the Extensions will enable APx to complete the Business Combination. APx can provide no assurances that the Business Combination will be consummated prior to the Extended Date. APx’s ability to consummate the Business Combination is dependent on a variety of factors, many of which are beyond APx’s control. Even if the Business Combination is approved by its shareholders, it is possible that redemptions will leave APx with insufficient cash to consummate the Business Combination on commercially acceptable terms, or at all. The fact that APx had and will have separate redemption periods in connection with the Extensions (as defined below) and the business combination vote could exacerbate these risks. Other than in connection with a redemption offer, Public Shareholders may be unable to recover their investment except through sales of Public Shares on the open market. The price of